Skip to main content
Erschienen in: Pituitary 4/2015

01.08.2015

Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function

verfasst von: Marie-Laure Persechini, Isabelle Gennero, Solange Grunenwald, Delphine Vezzosi, Antoine Bennet, Philippe Caron

Erschienen in: Pituitary | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A decrease of insulin-like growth factor-I levels (IGF-I) has been reported during the first trimester of pregnancy in women with acromegaly before the secretion of placental growth hormone (GH) progressively increases IGF-1 concentration.

Study design

To evaluate variations of concentrations of IGF-1, insulin-like growth factor (IGF)-binding protein-3 (IGF-BP3) and GH during the first trimester of pregnancy in women with normal somatotroph function.

Patients and methods

Sixteen women (median age 31 years) with as who were followed for benign thyroid disorders (n = 15) or prolactin-secreting microadenoma (n = 1) were evaluated before and in the first trimester of pregnancy. Serum concentrations of GH, IGF-1, IGF-BP3, TSH and estradiol (E2) were measured before and in the first trimester (5.4 ± 2.2 weeks of gestation).

Results

Before pregnancy, somatotroph and thyroid functions (median TSH 1.2 mU/L) were normal in all women. At the first trimester IGF-1 levels decreased significantly (before = 210 ng/mL, first trimester = 145 ng/mL, p < 0.001) with no significant change in GH (before = 1.5 ng/mL, first trimester = 0.84 ng/mL) or IGF-BP3 levels (before = 2.3 ng/mL, first trimester = 2.2 ng/mL), while estradiol levels increased significantly (before = 46.5 pg/100 mL, first trimester = 448.5 pg/100 mL, p < 0.001).

Conclusion

In women with normal somatotroph function, IGF-1 levels decrease in the first trimester of pregnancy without changes in GH or IGF-BP3 levels. These results confirm liver resistance to GH as a consequence of the physiological increase of estrogens during the first trimester.
Literatur
1.
Zurück zum Zitat Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melled S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148PubMedCrossRef Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melled S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148PubMedCrossRef
2.
Zurück zum Zitat Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG (2000) Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 85:1121–1125PubMedCrossRef Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG (2000) Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 85:1121–1125PubMedCrossRef
3.
Zurück zum Zitat Van der Klaauw AA, Biermasz NR, Zelissen PM, Pereira AM, Lentjes EG, Smit JW, van Thiel SW, Romijn JA, Roelfsema F (2007) Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. Eur J Endocrinol 157:709–716PubMedCrossRef Van der Klaauw AA, Biermasz NR, Zelissen PM, Pereira AM, Lentjes EG, Smit JW, van Thiel SW, Romijn JA, Roelfsema F (2007) Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. Eur J Endocrinol 157:709–716PubMedCrossRef
4.
Zurück zum Zitat Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA (2012) Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 166:207–213PubMedCrossRef Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA (2012) Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study. Eur J Endocrinol 166:207–213PubMedCrossRef
5.
Zurück zum Zitat Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693–721PubMedCrossRef Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693–721PubMedCrossRef
6.
Zurück zum Zitat Ovesen P, Vahl N, Fisker S, Veldhuis JD, Christiansen JS, Jørgensen JO (1998) Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women. J Clin Endocrinol Metab 83:1662–1667PubMedCrossRef Ovesen P, Vahl N, Fisker S, Veldhuis JD, Christiansen JS, Jørgensen JO (1998) Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women. J Clin Endocrinol Metab 83:1662–1667PubMedCrossRef
7.
Zurück zum Zitat Hudson SB, Schroeder DR, Bailey JN, Mielke KL, Erickson D, Miles JM, Bowers CY, Veldhuis JD (2010) Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. J Clin Endocrinol Metab 95:353–360PubMedCentralPubMedCrossRef Hudson SB, Schroeder DR, Bailey JN, Mielke KL, Erickson D, Miles JM, Bowers CY, Veldhuis JD (2010) Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. J Clin Endocrinol Metab 95:353–360PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Veldhuis JD, Hudson SB, Erickson D, Bailey JN, Reynolds GA, Bowers CY (2009) Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women. Am J Physiol Endocrinol Metab 297:E367–E374PubMedCentralPubMedCrossRef Veldhuis JD, Hudson SB, Erickson D, Bailey JN, Reynolds GA, Bowers CY (2009) Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women. Am J Physiol Endocrinol Metab 297:E367–E374PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Parkinson C, Ryder WD, Trainer PJ (2001) Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86:5240–5244PubMedCrossRef Parkinson C, Ryder WD, Trainer PJ (2001) Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86:5240–5244PubMedCrossRef
10.
Zurück zum Zitat Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265:E572–E577PubMed Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265:E572–E577PubMed
11.
Zurück zum Zitat Colao A, Merola B, Ferone D, Lombardi G (1997) Acromegaly. J Clin Endocrinol Metab 82:2777–2781PubMedCrossRef Colao A, Merola B, Ferone D, Lombardi G (1997) Acromegaly. J Clin Endocrinol Metab 82:2777–2781PubMedCrossRef
12.
Zurück zum Zitat Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155:279–284PubMedCrossRef Cozzi R, Attanasio R, Barausse M (2006) Pregnancy in acromegaly: a one-center experience. Eur J Endocrinol 155:279–284PubMedCrossRef
13.
Zurück zum Zitat Lau SL, McGrath S, Evain-Brion D, Smith R (2008) Clinical and biochemical improvement in acromegaly during pregnancy. J Endocrinol Invest 31:255–261PubMedCrossRef Lau SL, McGrath S, Evain-Brion D, Smith R (2008) Clinical and biochemical improvement in acromegaly during pregnancy. J Endocrinol Invest 31:255–261PubMedCrossRef
14.
Zurück zum Zitat Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95:4680–4687PubMedCrossRef Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P (2010) Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women. J Clin Endocrinol Metab 95:4680–4687PubMedCrossRef
15.
16.
Zurück zum Zitat Clapp JF 3rd, Schmidt S, Paranjape A, Lopez B (2004) Maternal insulin-like growth factor-I levels (IGF-I) reflect placental mass and neonatal fat mass. Am J Obstet Gynecol 190:730–736PubMedCrossRef Clapp JF 3rd, Schmidt S, Paranjape A, Lopez B (2004) Maternal insulin-like growth factor-I levels (IGF-I) reflect placental mass and neonatal fat mass. Am J Obstet Gynecol 190:730–736PubMedCrossRef
17.
Zurück zum Zitat Herman-Bonert V, Seliverstov M, Melmed S (1998) Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 83:727–731PubMed Herman-Bonert V, Seliverstov M, Melmed S (1998) Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab 83:727–731PubMed
18.
Zurück zum Zitat Beckers A, Stevenaert A, Foidart JM, Hennen G, Frankenne F (1990) Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 71:725–731PubMedCrossRef Beckers A, Stevenaert A, Foidart JM, Hennen G, Frankenne F (1990) Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab 71:725–731PubMedCrossRef
19.
Zurück zum Zitat Wilson DM, Bennett A, Adamson GD, Nagashima RJ, Liu F, DeNatale ML, Hintz RL, Rosenfeld RG (1982) Somatomedins in pregnancy: a cross-sectional study of insulin-like growth factors I and II and somatomedin peptide content in normal human pregnancies. J Clin Endocrinol Metab 55:858–861PubMedCrossRef Wilson DM, Bennett A, Adamson GD, Nagashima RJ, Liu F, DeNatale ML, Hintz RL, Rosenfeld RG (1982) Somatomedins in pregnancy: a cross-sectional study of insulin-like growth factors I and II and somatomedin peptide content in normal human pregnancies. J Clin Endocrinol Metab 55:858–861PubMedCrossRef
20.
Zurück zum Zitat Evain-Brion D, Malassine A (2003) Human placenta as an endocrine organ. Growth Horm IGF-1 Res 13 Suppl A: S34–37 Evain-Brion D, Malassine A (2003) Human placenta as an endocrine organ. Growth Horm IGF-1 Res 13 Suppl A: S34–37
21.
Zurück zum Zitat Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2010) Pregnancy and pituitary disorders. Eur J Endocrinol 162:453–475PubMedCrossRef Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F (2010) Pregnancy and pituitary disorders. Eur J Endocrinol 162:453–475PubMedCrossRef
22.
Zurück zum Zitat Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone: a review. Placenta 23 Suppl A:S87–94 Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone: a review. Placenta 23 Suppl A:S87–94
23.
Zurück zum Zitat Kam GY, Leung KC, Baxter RC, Ho KK (2000) Estrogens exert route-and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 85:1918–1922PubMed Kam GY, Leung KC, Baxter RC, Ho KK (2000) Estrogens exert route-and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 85:1918–1922PubMed
24.
Zurück zum Zitat Helle SI, Omsjø IH, Hughes SC, Botta L, Hüls G, Holly JM, Lønning PE (1996) Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol 45:727–732CrossRef Helle SI, Omsjø IH, Hughes SC, Botta L, Hüls G, Holly JM, Lønning PE (1996) Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol 45:727–732CrossRef
25.
Zurück zum Zitat Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E (2007) Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol 66:626–631CrossRef Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E (2007) Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol 66:626–631CrossRef
26.
Zurück zum Zitat Le Bouc Y (2007) IGF (insulin-like growth factors). In: Chanson P, Young J. Traité d’endocrinologie, pp 57–61. Editions Flammarion Médecine-Sciences, Paris Le Bouc Y (2007) IGF (insulin-like growth factors). In: Chanson P, Young J. Traité d’endocrinologie, pp 57–61. Editions Flammarion Médecine-Sciences, Paris
27.
Zurück zum Zitat Giudice LC, Farrell EM, Pham H, Lamson G, Rosenfeld RG (1990) Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab 71:806–816PubMedCrossRef Giudice LC, Farrell EM, Pham H, Lamson G, Rosenfeld RG (1990) Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity. J Clin Endocrinol Metab 71:806–816PubMedCrossRef
28.
Zurück zum Zitat Wiesli P, Zwimpfer C, Zapf J, Schmid C (2006) Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess. Acta Obstet Gynecol Scand 85:900–905PubMedCrossRef Wiesli P, Zwimpfer C, Zapf J, Schmid C (2006) Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess. Acta Obstet Gynecol Scand 85:900–905PubMedCrossRef
Metadaten
Titel
Decreased IGF-1 concentration during the first trimester of pregnancy in women with normal somatotroph function
verfasst von
Marie-Laure Persechini
Isabelle Gennero
Solange Grunenwald
Delphine Vezzosi
Antoine Bennet
Philippe Caron
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 4/2015
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-014-0596-3

Weitere Artikel der Ausgabe 4/2015

Pituitary 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.